A Phase 2/3 trial of BBP-711 in primary hyperoxaluria type 1
Latest Information Update: 04 Jul 2022
At a glance
- Drugs BBP-711 (Primary)
- Indications Primary hyperoxaluria type 1
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors BridgeBio Pharma
- 27 Jul 2022 According to BridgeBio Pharma media release, the company has met with regulators and intends to initiate this study by the end of 2022.
- 03 Jan 2022 New trial record